New study shows popular GLP-1 weight loss drug may slow biological aging
www.universityofcalifornia.edu
A new study provides the first clinical evidence that popular semaglutide drugs, like Ozempic or Wegovy, could slow down processes associated with biological aging.
  • jet@hackertalks.comEnglish
    10·
    17 days ago

    May also means may not

    We can rewrite the title as

    Glp1s may not slow biological aging

    • boonhet@lemmy.zipEnglish
      3·
      17 days ago

      However, the study found compared to the placebo group:

      • Participants treated with semaglutide exhibited a broad pattern of slower biological aging across epigenetic clocks linked to inflammation and blood, brain, heart, kidney, liver and metabolic health.

      • The drug slowed the pace of biological aging by 9 %, as measured by the DunedinPACE epigenetic clock.

      • The drug significantly slowed biological processes associated with the risk of all‑cause mortality and age-related disease, as measured by the PCGrimAgeepigenetic clock.

      It’s just that the study focused on people with a particular condition so it takes more studies to know if it affects the general population similarly.

      • jet@hackertalks.comEnglish
        3·
        17 days ago

        are these unique to the glp-1 intervention or are they echos of ketone production, fat metabolism, increased insulin sensitivity… are there more effective ways to achieve the same marker improvements without using a glp-1? (obviously yes)

        Making casual claims like slow biological aging requires the context which the data is based, and a demonstration of the mechanisms.